Page 2 - Nasdaq Eigr News Today

StockNews.com began coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report released on Saturday. The firm issued a sell rating on the biotechnology company’s stock. Separately, Citigroup reduced their price objective on Eiger BioPharmaceuticals from $4.00 to $3.00 and set a buy rating for the company in a research note […]

StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report sent to investors on Friday. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, Citigroup decreased their target price on Eiger BioPharmaceuticals from $4.00 to $3.00 and set a buy rating for the company in a […]

StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, Citigroup dropped their price objective on Eiger BioPharmaceuticals from $4.00 to $3.00 and set a buy rating on the stock in […]

StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a report published on Thursday. The firm issued a sell rating on the biotechnology company’s stock. Separately, Citigroup reduced their price target on Eiger BioPharmaceuticals from $4.00 to $3.00 and set a buy rating for the company in a report on Tuesday, […]

Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Free Report) will release its earnings data on Friday, November 3rd. Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Free Report) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter. Eiger BioPharmaceuticals had a negative return on equity of 207.93% […]

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Get Free Report) saw a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,160,000 shares, a drop of 7.2% from the September 15th total of 1,250,000 shares. Based on an average daily trading volume, of 289,900 shares, the days-to-cover […]

StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Several other equities analysts also recently weighed in on EIGR. Citigroup reduced their target price on Eiger BioPharmaceuticals from $4.00 to $3.00 and set […]

StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research note released on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Citigroup lowered their target price on shares of Eiger BioPharmaceuticals from $4.00 […]

StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock. EIGR has been the subject of several other reports. Citigroup lowered their target price on Eiger BioPharmaceuticals from $4.00 to $3.00 and set […]

Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) had its price target reduced by Citigroup from $4.00 to $3.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the company. StockNews.com downgraded Eiger BioPharmaceuticals from a […]